Matthias Schwab

Innsbruck Medical University — Austria

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

121h-index69.9kcitations1.3kworks3.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(187), Drug Transport and Resistance Mechanisms(154), Acute Lymphoblastic Leukemia research(84), Estrogen and related hormone effects(65), Pharmacological Effects and Toxicity Studies(62)

Publications1.3k total

Quantitative analysis of underivatised short-chain fatty acids and simultaneous non-targeted metabolic profiling by ultra-high performance liquid chromatography-mass spectrometry
Microchemical Journal·2025
Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study
EClinicalMedicine·2025Open Access
A predictive model for life-threatening fluoropyrimidine toxicity based on <i>DPYD</i> sequencing in colorectal cancer
JNCI Journal of the National Cancer Institute·2025
Tamoxifen metabolites acting via BKCa orchestrate the dynamics of K+ and Ca2+ in breast cancer cells
Journal of Biological Chemistry·2025Open Access
Supplementary Table S4 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Supplementary Figure S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Drug targeting of the monocarboxylate transporter MCT4 is a novel treatment strategy for metastatic ccRCC
Pharmacological Research·2025Open Access
Supplementary Table S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Supplementary Table S1 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Supplementary Table S3 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Supplementary Table S5 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Supplementary Figure S2 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Supplementary Table S6 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Supplementary Table S7 from Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial
2025Open Access
Feasibility of Patient-Derived 3D Gastrointestinal Stromal Tumour Models as Alternatives for In Vivo Mouse Models
International Journal of Molecular Sciences·2025Open Access
Clinical outcomes of drug-coated balloon vs. second-generation drug-eluting stent for coronary in-stent restenosis
Clinical Research in Cardiology·2025· 1 citedOpen Access
Publisher Correction: Academia Europaea’s guidelines for the visualization of clinical outcomes
Nature Medicine·2025Open Access
Gαi2 Signaling Regulates Neonatal Respiratory Adaptation
International Journal of Molecular Sciences·2025Open Access
Safety and efficacy of monoclonal antibody therapy in patients with chronic herpes simplex virus-2 genital infections: MATCH-2, a randomized double-blinded, parallel-group phase 2 multi-center trial
Pharmacological Research·2025· 2 citedOpen Access
Multiple Sclerosis Relapse Treatment During Pregnancy and Offspring Functional and Structural Neurodevelopment
Neurology·2025· 2 citedOpen Access
page 1 of 67Next →

Frequent Co-authors

Ulrich M. Zanger(15), Michel Eichelbaum(13), Elke Schaeffeler(12), Teri E. Klein(7), Eduard F. Stange(6), Kathrin Klein(6), Jan Wehkamp(5), Klaus Fellermann(5), Péter Fritz(5), Kelly E. Caudle(5), Charles Bevins(4), Jesse J. Swen(4), Mary V. Relling(4), Michelle Whirl‐Carrillo(4), Thomas Lang(4), Joachim E. Fischer(4), Oliver Burk(4), Martin F. Fromm(4), Reinhold Kerb(4), Anne T. Nies(4)